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Brief Clinical ReportsExtracorporeal membrane oxygenation via sternotomy for
circulatory shockStephen Horton, PhD,a,c Yves d’Udekem, MD,a,c Frank Shann, MD,b Warwick Butt, MBBS,b
Martin Bennett, BAppSc,a Derek Best, RN,b and Christian Brizard, MD,a,c Victoria and Melbourne,
AustraliaExtracorporeal membrane oxygenation (ECMO) has been
used to treat sepsis in children at the Royal Children’s Hos-
pital since 1988, with overall survival of 47%. Before 2000,
our pediatric population requiring mechanical support for
sepsis was supported with ECMO with cannulae implanted
peripherally in the right common carotid artery and the right
internal jugular vein. Since 2000, to improve delivered
flows, we started to cannulate directly the aorta and right
atrium through a sternotomy.PATIENTS AND METHODS
From 1988 to 2007, 47 pediatric patients had ECMO support for sepsis
(Table 1) using our technique as previously described.1 Meningococcal sep-
ticemia was the single largest group (n¼ 13). Indications for ECMO for sep-
tic shock were severe hypotension, evidence of inadequate end-organ
perfusion (persistent metabolic acidosis, renal failure) despite adequate fluid
resuscitation, and high-dose inotropic support (adrenaline>1 mg $ kg1 $
min1 or the need for repeated bolus doses of adrenaline or external cardiac
massage). ECMO was considered in patients with respiratory failure if ven-
tilator target values (pH>7.25, arterial oxygen saturation>88%) could not
be achieved with mechanical ventilation with a fractional inspired oxygen
concentration (FiO2) less than 0.9 and high positive end expiratory pressure
(PEEP), long inspiratory time, change in patient position, or high-frequency
oscillatory ventilation. Patients were excluded from ECMO if they had re-
ceived high-pressure mechanical ventilation with a peak inspiratory pres-
sure (PIP)>35 cm H2O, had an FIO2>0.6 for more than 10 to 14 days,
or had underlying irreversible disease or evidence of a recent cerebral hem-
orrhage.
All patients required venoarterial ECMO using the highest flows (150 to
300 mL/kg/min) achievable to maintain adequate peripheral perfusion.
ECMO flow rates were adjusted to achieve maximal systemic perfusion at
age-appropriate perfusion pressures, where cannula size permitted. Systemic
perfusion was judged to be adequate if there was correction of metabolic ac-
idosis, an arterial oxygen saturation of more than 90%, and a mixed venous
oxygen saturation of more than 65%. If adequate perfusion was not achieved
in patients who were cannulated peripherally with a right internal jugular ve-From the Department of Cardiac Surgery,a Royal Children’s Hospital, Victoria,
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used. All patients received a continuous heparin infusion for anticoagulation,
titrated to achieve an activated clotting time of 160 seconds (MAX-ACT,
Helena laboratories, Beaumont, Tex), with platelet count maintained at
more than 100,000/mL. If chest drain blood loss was greater than 5 mL $
kg1 $ min1, then aprotinin was infused at 10,000 kIU $ kg1 $ h1; In 5 pa-
tients, bleeding persisted despite surgical reexploration. Heparin was
stopped and prostacyclin infused at 5 ng $ kg1 $ min1.
Once adequate ECMO flow had been established, the ventilator settings
were reduced (PIP<25 cm H2O, PEEP 10 cm H2O, 10 breaths/minute, FIO2
0.21 to 0.30) to minimize iatrogenic lung damage. When satisfactory sys-
temic perfusion had been achieved on ECMO, inotrope infusions were
reduced to optimize conditions for myocardial recovery. Continuous hemo-
filtration was undertaken where necessary for renal replacement therapy.
Wilcoxon rank-sum test was used to test whether there were any significant
differences between the 2 groups (Table 1) or difference in outcome (P¼ .02).
RESULTS
In group 1 (n¼ 35), the cannulae were surgically inserted
in the peripheral vessels (neck or groin) with 1 or more ve-
nous cannulae. In group 2 (n ¼ 12), a median sternotomy
was performed, and the ECMO was instituted between the
body of the right atrium and the ascending aorta. The max-
imal achievable mean ECMO flow averaged for the first 24
hours was 2.40 L $ min1 $ m2 in group 1, and 3.43 L $
min1 $ m2 in group 2 (P ¼ .002). There were 22 deaths
in group 1 (63%) and 3 deaths in group 2 (25%; P ¼
0.02). Transthoracic cannulation has been described to in-
crease the risk of bleeding (31.4 vs 0.9 mL/kg) as well as
the incidence of nosocomial infection (36% vs 19%)2; how-
ever, we found no difference with blood requirements be-
tween the 2 groups (Table 1) or the rate of nosocomial
infection (37% vs 33%).
The 2005 Pediatric Sepsis Consensus criteria were used to
define septic shock and organ dysfunction,3 and on admis-
sion to the intensive care unit, all patients were receiving
antibiotics and had positive bacterial cultures (except for
a single patient with positive viral immunofluorescence
from a lower respiratory tract sample).DISCUSSION
Sepsis is common in patients in intensive care in Australia;
as well as increasing morbidity, it is an important cause of
mortality and has become the second commonest cause of
death in preterm infants. In our retrospective report encom-
passing the last 20 years, septic shock necessitating ECMO
constituted 10% of extracorporeal life support (ECLS).ery c February 2010
TABLE 2. Median patient biochemistry results of the 2 groups (sternotomy/carotid artery–jugular vein cutdown) immediately prior to and 24 and
156 hours after ECMO institution
Hb (g/L) Lactate (mmol/L) Creatinine (mmol/L) Albumin (g/L)
Pre 100/120 6.0/8.2 0.11/0.09 23/34
P value .40 .32 .39 .05
24 h 94.5/119 3.1/5.8 0.11/0.09 28/35
P value .03 .03 .30 .07
156 h 116.5/118 1.0/1.7 0.07/0.10 30/34
P value .69 .001 .96 .20
ECMO, Extracorporeal membrane oxygenation.
TABLE 1. Median patient variables immediately prior to ECMO and blood product use during ECMO
Carotid artery/jugular vein
cutdown median
(interquartile
range), group 1
Sternotomy, median
(interquartile range),
group 2
P
value
Age (mo) 17 (1.5–90) 47.5 (6.3–153.2) .17
Surface area (m2) 0.46 (0.23–0.86) 0.85 (0.31–1.38) .16
Sex (% males) 63 67
Hours ICU pre-ECMO 21.7 (3.9–28.3) 10.3 (6.2–38.6) .73
Average flow L/m2 first 24 h 2.40 (2.39–2.73) 3.43 (2.93–4.57) .002
Hours on ECMO 99 (38–165) 87 (23–119) .07
Blood pressure (mm Hg) 48 (38–70) 53 (38–62) .96
pH prior to ECMO 7.25 (7.15–7.33) 7.11 (7.03–7.29) .04
Packed red cells (mL $ kg1 $ h1) 1.0 (0.5–2.3) 1.3 (0.6–4.3) .48
Platelets (mL $ kg1 $ h1) 0.56 (0.26–1.57) 0.6 (0.3–1.3) .94
Fresh frozen plasma (mL $ kg1 $ h1) 0.62 (0.06–1.43) 1.2 (0.2–2.2) .15
ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit.
Brief Clinical ReportsEighteen patients prior to institution of venoarterial ECMO
were receiving chest compressions as they were in cardiac
arrest, with 41 patients having failure of at least 3 organ
systems and 28 requiring hemofiltration (reducing incidence
of edema in either group). Randomized controlled trails for
ECMO have been undertaken by others4; however, studies
utilizing different cannulation sites for septic shock are
unlikely to be performed due to the poor outcome in the
peripheral cannulation group, which necessitated that we
use a novel alternative. The institution of ECMO via
transthoracic cannulation allowed us to achieve adequate
metabolic support using larger cannulae than with percutane-
ous cannulation of the jugular or femoral veins, with flows of
3.43 L $ min1 $ m2 versus 2.40 L $ min1 $ m2 (P¼ 0.002).
The introduction of new technology1 allowed us to make use
of high-flow ECMO, which even with cannulation via ster-
notomy would not have been able to achieve these flows as
our previous ECMO circuit was a high resistance system.5
Also, Traysylol, which has been used in both groups but to
a greater extent in the sternotomy group, may have been
a contributing factor in there being no difference in blood
product transfusion. With this product having probable fu-
ture limited availability, we are currently researching novel
anticoagulation regimens utilizing low-dose heparin (10 IUThe Journal of Thoracic and Ca$ kg1 $ h1) in conjunction with platelet suppression (prosta-
cyclin 5 ng $ kg1 $ h1 and nitric oxide 5 ppm into the ven-
tilating gas of the oxygenator). Elevations of markers of
end-organ function (lactate, creatinine, liver enzymes) before
and soon after starting ECMO are associated with increased
mortality; early, marked elevations identify those children
likely to require support, as well as reflect the effectiveness
of resuscitative efforts. We have found that high-flow
ECMO via central access sternotomy optimizes end-organ
perfusion as evidenced by a significantly lower lactate at
24 and 156 hours (Table 2) with a significant improvement
in survival.References
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